Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | XPO1 | O14980 | 14/20 | 1.00 |
| ▸ | RANBP1 | P43487 | 1/20 | 1.00 |
| ▸ | KCNH2 | Q12809 | 1/20 | 1.00 |
| ▸ | ESR1 | P03372 | 1/20 | 0.48 |
| ▸ | HTR1A | P08908 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.48 |
| ▸ | HRH1 | P35367 | 1/20 | 0.48 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.48 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.48 |
| ▸ | EGFR | P00533 | 2/20 | 0.33 |
| ▸ | KDR | P35968 | 2/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.33 |
| ▸ | CDK1 | P06493 | 1/20 | 0.33 |
| ▸ | PIM1 | P11309 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | GSK3B | P49841 | 1/20 | 0.33 |
| ▸ | CDK5 | Q00535 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Eltanexor SCHEMBL16323700 | 1.00 | XPO1 (1.00) | XPO1RANBP1KCNH2ESR1HTR1A | |
| Eltanexor SCHEMBL16323699 | 1.00 | XPO1 (1.00) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL26308291 | 0.95 | XPO1 (0.90) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL26312767 | 0.94 | XPO1 (0.88) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23133144 | 0.93 | XPO1 (0.86) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL16361454 | 0.93 | XPO1 (0.86) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788773 | 0.93 | XPO1 (0.86) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL23133415 | 0.93 | XPO1 (0.86) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL17788774 | 0.93 | XPO1 (0.86) | XPO1RANBP1KCNH2ESR1HTR1A | |
| SCHEMBL21588154 | 0.92 | XPO1 (0.85) | XPO1RANBP1KCNH2ESR1HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 380 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-122075708-A | Application of XPO1 inhibitor in preparing medicine for locally treating pruritus | — | 2026-05-26 | — | — | CN | claimed |
| EP-4727933-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | Board of Regents, The University of Texas System (US) | 2026-04-22 | — | — | EP | claimed |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | OTSUKA PHARMA CO LTD (JP) | 2026-01-01 | — | — | US | claimed |
| US-20250161346-A1 | METHODS FOR TREATING HEPATITIS B VIRUS INFECTION | Shih, Chiaho (US) | 2025-05-22 | — | — | US | claimed |
| WO-2025043187-A1 | FIXED DOSE COMBINATIONS OF CEDAZURIDINE AND AZACITIDINE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2025-02-27 | — | — | WO | claimed |
| WO-2024263573-A1 | COMBINATION THERAPY METHODS FOR TREATING TP53-Y220C MUTANT AND TP53 WILDTYPE LEUKEMIAS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2024-12-26 | — | — | WO | claimed |
| CN-119072303-A | Combined preparation of sitagliptin | 大塚制药株式会社 | 2024-12-03 | — | — | CN | claimed |
| US-20240277810-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. | 2024-08-22 | — | — | US | claimed |
| CN-118436669-A | Pancreatic cancer tumor resisting pharmaceutical composition and application thereof | 中山大学孙逸仙纪念医院 | 2024-08-06 | — | — | CN | claimed |
| US-20240254564-A1 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2024-08-01 | — | — | US | claimed |
| EP-4225281-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | Merck Patent GmbH (DE) | 2023-08-16 | — | — | EP | claimed |
| CN-116528877-A | LMP7 selective inhibitors for the treatment of blood disorders and solid tumors | 默克专利股份公司 | 2023-08-01 | — | — | CN | claimed |
| WO-2022256371-A1 | METHODS FOR PREDICTING AND TREATING CHEMORESISTANCE IN SMALL CELL LUNG CANCER PATIENTS | MEMORIAL SLOAN-KETTERING CANCER CENTER (US) | 2022-12-08 | — | — | WO | claimed |
| WO-2022256211-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-20220323406-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2022-10-13 | — | — | US | claimed |
| US-20220249486-A1 | SETBP1 AND XPO1 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA | THE HENRY M. JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE, INC. | 2022-08-11 | — | — | US | claimed |
| US-20220218725-A1 | METHODS AND MATERIALS FOR TREATING CANCER | MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH | 2022-07-14 | — | — | US | claimed |
| WO-2022087526-A1 | METHODS AND COMPOSITIONS FOR DIFFERENTIATING STEM CELLS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2022-04-28 | — | — | WO | claimed |
| WO-2022073994-A1 | LMP7-SELECTIVE INHIBITORS FOR THE TREATMENT OF BLOOD DISORDERS AND SOLID TUMORS | MERCK PATENT GMBH (DE) | 2022-04-14 | — | — | WO | claimed |
| EP-3968987-A1 | METHODS AND MATERIALS FOR TREATING CANCER | Mayo Foundation for Medical Education and Research (US) | 2022-03-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240277810-A1 | INTERFERONS AND NUCLEAR EXPORT INHIBITORS FOR USE IN METHODS OF TREATING CANCER | XPOT, XPO1, IFNAR1 | XPO1 2/4885RANBP1 13/4885KCNH2 4861/4885 |
| US-20220218725-A1 | METHODS AND MATERIALS FOR TREATING CANCER | DDX21, LMNB1, XPOT | XPO1 9/4885RANBP1 499/4885KCNH2 4845/4885 |
| US-20260000697-A1 | COMBINATION FORMULATION OF CEDAZURIDINE | DCTD, EZH2, DUT | XPO1 1108/4885RANBP1 4010/4885KCNH2 4625/4885 |
| US-20220249486-A1 | SETBP1 AND XPO1 INHIBITORS FOR THE TREATMENT OF SICKLE CELL DISEASE AND BETA-THALASSEMIA | XPO1, XPO4, FUBP1 | XPO1 1/4885RANBP1 13/4885KCNH2 4622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.